Market revenue in 2022 | USD 232.6 million |
Market revenue in 2030 | USD 1,536.9 million |
Growth rate | 26.6% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 67.84% in 2022. Horizon Databook has segmented the South Korea cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea is the 12th largest market in the healthcare industry. The South Korean government has planned to invest more than USD 1.7 billion in the country's biotechnology and biopharmaceutical sector. The country is one of the key markets for regenerative medicine as it was the first to commercialize stem cell therapy.
The Korean government is also supportive of the adoption of cell and gene therapy products. For instance, in 2019, the government passed the Act on the Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals that allows conditional approval for commercial sale of phase II completed drugs.
Such favorable government initiatives are expected to accelerate growth of cell and gene therapy manufacturing market. Furthermore, Samsung Biologics is a leading South Korean company that operates in this space.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into South Korea cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account